AU2021376885A1 - Prophylaxis and treatment of angioedema - Google Patents

Prophylaxis and treatment of angioedema Download PDF

Info

Publication number
AU2021376885A1
AU2021376885A1 AU2021376885A AU2021376885A AU2021376885A1 AU 2021376885 A1 AU2021376885 A1 AU 2021376885A1 AU 2021376885 A AU2021376885 A AU 2021376885A AU 2021376885 A AU2021376885 A AU 2021376885A AU 2021376885 A1 AU2021376885 A1 AU 2021376885A1
Authority
AU
Australia
Prior art keywords
compound
solvate
pharmaceutically acceptable
acceptable salt
angioedema
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021376885A
Other languages
English (en)
Other versions
AU2021376885A9 (en
Inventor
Anne Lesage
Peng Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharvaris GmbH
Original Assignee
Pharvaris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris GmbH filed Critical Pharvaris GmbH
Publication of AU2021376885A1 publication Critical patent/AU2021376885A1/en
Publication of AU2021376885A9 publication Critical patent/AU2021376885A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021376885A 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema Pending AU2021376885A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20207273 2020-11-12
EP20207273.2 2020-11-12
PCT/EP2021/081493 WO2022101395A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Publications (2)

Publication Number Publication Date
AU2021376885A1 true AU2021376885A1 (en) 2023-06-08
AU2021376885A9 AU2021376885A9 (en) 2024-10-24

Family

ID=73401436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021376885A Pending AU2021376885A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Country Status (12)

Country Link
US (1) US20230338358A1 (https=)
EP (1) EP4243824B1 (https=)
JP (1) JP2023549849A (https=)
KR (1) KR20230107269A (https=)
CN (1) CN116685353A (https=)
AU (1) AU2021376885A1 (https=)
CA (1) CA3198246A1 (https=)
ES (1) ES3061585T3 (https=)
IL (1) IL302887A (https=)
MX (1) MX2023005563A (https=)
WO (1) WO2022101395A1 (https=)
ZA (1) ZA202305122B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3062067T3 (en) * 2022-03-25 2026-04-08 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
WO2025037920A1 (ko) 2023-08-16 2025-02-20 주식회사 엘지화학 수지 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053660A2 (en) * 2003-12-03 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising danazol
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
AR113839A1 (es) * 2017-11-24 2020-06-17 Pharvaris B V Antagonistas del receptor b2 de bradiquinina

Also Published As

Publication number Publication date
EP4243824B1 (en) 2025-12-24
MX2023005563A (es) 2023-09-11
ES3061585T3 (en) 2026-04-06
WO2022101395A1 (en) 2022-05-19
ZA202305122B (en) 2024-08-28
CN116685353A (zh) 2023-09-01
CA3198246A1 (en) 2022-05-19
IL302887A (en) 2023-07-01
KR20230107269A (ko) 2023-07-14
EP4243824A1 (en) 2023-09-20
US20230338358A1 (en) 2023-10-26
JP2023549849A (ja) 2023-11-29
EP4243824C0 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
TWI777515B (zh) 治療嗜伊紅性食道炎之方法
EP4243824B1 (en) Prophylaxis and treatment of angioedema
EP4003327B1 (en) Compounds for use in the treatment of paroxysmal nocturnal haemoglobinuria (pnh)
Chapman et al. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers
US20180161314A1 (en) Methods for Treating Hyperuricemia and Related Diseases
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
US20240197739A1 (en) Combination Comprising Ribociclib and Amcenestrant
US20230404971A1 (en) Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid
EP4342475A1 (en) Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
AU2016244263A1 (en) Combination ALS therapy
TW200815014A (en) Method of improved diuresis in individuals with impaired renal function
JPH11507012A (ja) 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療
HK40099091A (en) Prophylaxis and treatment of angioedema
HK40099091B (en) Prophylaxis and treatment of angioedema
CN115135326B (zh) 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
Massie et al. Antihypertensive effects of mibefradil: A double‐blind comparison with diltiazem CD
Esseku et al. A randomized Phase I bioequivalence clinical trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers
US20250339442A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
CN113226374B (zh) 含氨氯地平、氯噻酮和醛固酮受体拮抗剂的药物组合物
KR20240019265A (ko) Mmp-12 억제제의 안전한 투여
KR19980702100A (ko) 심장혈관질환의 치료를 위한 안지오텐신 전환 효소 억제제, 부작용-감소된 양의 알도스테론 길항제 및 이뇨제의 조합 치료요법
HK40058710A (en) Dosing regimens for the treatment of pompe disease
Seedat The long-term efficacy and tolerability of nisoldipine in patients with mild-to-moderate hypertension
WO2020207355A1 (zh) 含氨氯地平、氯噻酮和阿米洛利的药物组合物

Legal Events

Date Code Title Description
SREP Specification republished